Novo partners with Hims to expand US access to Ozempic and Wegovy

1) Hims & Hers to offer branded Ozempic and Wegovy; compounding ads to stop

Novo said the agreement takes effect later this month, giving Hims & Hers customers access to FDA-approved Ozempic injections and Wegovy injections plus Wegovy tablets (oral) at Novo’s self-pay prices. Hims will no longer advertise compounded GLP-1s and will transition existing patients to FDA-approved options when clinically appropriate.

2) Novo dismisses patent infringement lawsuit against Hims, retains refile option

Novo is dismissing its patent infringement lawsuit tied to compounded GLP-1 promotion by Hims & Hers, while explicitly reserving the right to refile in the future. The legal truce reduces near-term dispute over the channel, but keeps leverage if Hims reverts to non-branded offerings.

3) Wegovy pill positioned on efficacy and CV risk-reduction label

Novo highlighted OASIS 4 results for once-daily oral semaglutide 25 mg (Wegovy pill): ~16.6% average weight loss under the trial product estimand vs ~2.7% placebo, and ~13.6% vs ~2.4% under the treatment policy estimand, with GI side effects consistent with injectable Wegovy. Novo also reiterated the MACE risk-reduction indication for Wegovy pill in adults with CVD and overweight/obesity.

4) Stock lifted as investors focus on tighter control of GLP-1 distribution

The market response centred on Novo expanding branded reach through a large consumer telehealth platform while pushing back on compounded alternatives. With self-pay pricing maintained in the arrangement, the announcement was read as supportive of access expansion without signalling a new price reset in this channel.

Novo Nordisk rose on the day, with trading sentiment supported by the Hims & Hers access deal and the removal of an active legal overhang. The move also reflected broader investor focus on branded GLP-1 channel control versus compounded substitutes.

Latest close: DKK 254.50 (+2.66%)